These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 35589257)

  • 1. Promises of microbiome-based therapies.
    Bajaj JS; Ng SC; Schnabl B
    J Hepatol; 2022 Jun; 76(6):1379-1391. PubMed ID: 35589257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies.
    Koning M; Herrema H; Nieuwdorp M; Meijnikman AS
    Gut Microbes; 2023; 15(1):2226922. PubMed ID: 37610978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiome as a therapeutic target in alcohol-related liver disease.
    Sarin SK; Pande A; Schnabl B
    J Hepatol; 2019 Feb; 70(2):260-272. PubMed ID: 30658727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature.
    Giuffrè M; Campigotto M; Campisciano G; Comar M; Crocè LS
    Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G889-G906. PubMed ID: 32146836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the microbiome in liver disease.
    Schöler D; Schnabl B
    Curr Opin Gastroenterol; 2024 May; 40(3):134-142. PubMed ID: 38362864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut mycobiome in metabolic diseases: Mechanisms and clinical implication.
    Zhou X; Zhang X; Yu J
    Biomed J; 2024 Jun; 47(3):100625. PubMed ID: 37364760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut dysbiosis and age-related neurological diseases; an innovative approach for therapeutic interventions.
    Holmes A; Finger C; Morales-Scheihing D; Lee J; McCullough LD
    Transl Res; 2020 Dec; 226():39-56. PubMed ID: 32755639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles for the mycobiome in liver disease.
    Zeng S; Schnabl B
    Liver Int; 2022 Apr; 42(4):729-741. PubMed ID: 34995410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
    Leclercq S; de Timary P; Stärkel P
    Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: An emerging trend in cancer patient care.
    Ciernikova S; Sevcikova A; Drgona L; Mego M
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188990. PubMed ID: 37742728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of gut microbiota to drug-induced liver injury.
    Chu HK; Ai Y; Cheng ZL; Yang L; Hou XH
    Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):458-465. PubMed ID: 37365109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease.
    Yadav A; Yadav R; Sharma V; Dutta U
    Indian J Gastroenterol; 2024 Feb; 43(1):112-128. PubMed ID: 38409485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Microbiome-Based Therapies in Chronic Respiratory Diseases.
    Lee SH; Lee JH; Lee SW
    J Microbiol; 2024 Mar; 62(3):201-216. PubMed ID: 38635003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
    Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
    J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut Microbiota and Diarrhea: An Updated Review.
    Li Y; Xia S; Jiang X; Feng C; Gong S; Ma J; Fang Z; Yin J; Yin Y
    Front Cell Infect Microbiol; 2021; 11():625210. PubMed ID: 33937093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of the gut virome and mycobiome in faecal microbiota transplantation.
    Lam S; Bai X; Shkoporov AN; Park H; Wu X; Lan P; Zuo T
    Lancet Gastroenterol Hepatol; 2022 May; 7(5):472-484. PubMed ID: 35276080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Link between Gut Microbiota and Hepatic Encephalopathy.
    Won SM; Oh KK; Gupta H; Ganesan R; Sharma SP; Jeong JJ; Yoon SJ; Jeong MK; Min BH; Hyun JY; Park HJ; Eom JA; Lee SB; Cha MG; Kwon GH; Choi MR; Kim DJ; Suk KT
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.